Exploration and Incentivizing Participation in Randomized Trials
Yingkai Li, Aleksandrs Slivkins

TL;DR
This paper addresses the challenge of incentivizing participation in randomized controlled trials by framing it as an exploration-exploitation tradeoff and proposing mechanisms that improve statistical performance while encouraging agent involvement.
Contribution
It introduces a novel incentive-compatible mechanism for RCT participation, providing near-optimal solutions and analyzing different agent heterogeneity scenarios.
Findings
Achieves near-optimal worst-case estimation error guarantees.
Provides a nearly matching impossibility result for incentive-compatible mechanisms.
Extends the model to heterogeneous agents and uses estimated type frequencies.
Abstract
Participation incentives is a well-known issue inhibiting randomized controlled trials (RCTs) in medicine, as well as a potential cause of user dissatisfaction for RCTs in online platforms. We frame this issue as a non-standard exploration-exploitation tradeoff: an RCT would like to explore as uniformly as possible, whereas each "agent" (a patient or a user) prefers "exploitation", i.e., treatments that seem best. We incentivize participation by leveraging information asymmetry between the trial and the agents. We measure statistical performance via worst-case estimation error under adversarially generated outcomes, a standard objective for RCTs. We obtain a near-optimal solution in terms of this objective: an incentive-compatible mechanism with a particular guarantee, and a nearly matching impossibility result for any incentive-compatible mechanism. We consider three model variants:…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPharmaceutical Economics and Policy · Health Systems, Economic Evaluations, Quality of Life · Statistical Methods in Clinical Trials
